Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has reported a robust growth for the first half of 2024, with a substantial increase in revenue by 32.2% and a dramatic rise in gross profit by 59.4% compared to the same period in 2023. The biopharmaceutical company also highlighted positive developments and breakthrough designations for their core product sac-TMT, which showed promising results in clinical trials for various cancers. The financial performance and clinical advancements signal a strong upward trajectory for the company’s future.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.